Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Front Med (Lausanne) · 2024 · PMC11544541 · PMID 39526247

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

3.4 months), although the between-group differences did not reach statistical significance ( 63 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.